ライフサイエンスコーパス: microneedle

1 cation methods e.g. lateral application of a microneedle.

2 low, coated, dissolving and hydrogel forming microneedles.

3 egaderm, Listerine tabs, and stainless steel microneedles.

4 1microl/s) by exploiting capillarity in the microneedles.

5 n of Wistar rats using NanoPass MicronJet600 microneedles.

6 eat-labile enterotoxin (dmLT) adjuvant using microneedles.

7 f thin PLGA films by stamping with blunt-tip microneedles.

8 a substrate for the formation of dissolvable microneedles.

9 peanut cutaneous immunotherapy using coated microneedles.

10 and similar vertical penetration depths for microneedling, AFXL, and non-AFXL (median, 125 mum).

11 atially resolved zones of active and passive microneedles allow a combinatorial rapid burst response

12 In summary, quininib-HA microneedles allow for sustained release of quininib; ar

13 They were blinded to the laterality of microneedle and sham roller assignments.

14 was not significantly different between the microneedle and sham sides (0.7 and 0.4; P = .28), respe

15 was not significantly different between the microneedle and sham sides, 4.5 mm and 3.4 mm (P = .21),

16 Bubble structures between each microneedle and the patch backing allow the microneedles

17 optimized to achieve higher 5-ALA loading on microneedles and a high delivery efficiency into porcine

18 on conditions, two different crystal shapes, microneedles and microribbons, are grown on a clean wate

19 ntial strategies for designing antimicrobial microneedles and their targeted therapy are outlined.

20 Polymers, lipids, scaffolds, microneedles, and other biomaterials are rapidly emergin

21 pretreatment, followed by microdermabrasion, microneedling, and curettage.

22 The microneedle aperture was modified by electropolymerizing

23 arable to that achieved by the most invasive microneedle application methods e.g. lateral application

24 ms transferred into the skin following brief microneedle application promoted local transfection and

25 Solid microneedles are modified with different coatings and po

26 Microneedles are the micrometer size devices used for th

27 ntradermal delivery system with a dissolving microneedle array (DMNA).

28 imize the side effects, we developed a novel microneedle array (MNA) that could deliver live attenuat

29 Microneedle array (MNA)-based electrochemical sensors of

30 el influenza vaccine-packaged, biodegradable microneedle array (MNs), mice displayed vigorous antigen

31 nd in vivo after discretised puncturing by a microneedle array (Nanopatch(R)).

32 ought to develop a powder-laden, dissolvable microneedle array (PLD-MNA) for epidermal delivery of po

33 r, antigen loaded NPs delivered via a hollow microneedle array elicited a significantly higher IgG2a

34 study, we investigated the use of the hollow microneedle array for intradermal delivery of polymeric

35 first time the ability of the solid silicon microneedle array for punching holes to deliver choleste

36 B along with glucose and lactate on a single microneedle array has been demonstrated.

37 ermal delivery of polymeric NPs via a hollow microneedle array resulted in a unique pharmacokinetic p

38 The performance of the microneedle array, second generation biosensor for lacta

39 and soluble antigen delivered through hollow microneedle array.

40 ive insulin delivery device using a painless microneedle-array patch ("smart insulin patch") containi

41 Microneedle arrays (MNAs) are emerging as an effective t

42 a three-component Protein Subunit vaccine on Microneedle Arrays (PSMNs) for transcutaneous delivery u

43 ts the potential success of hydrogel-forming microneedle arrays as a transdermal drug delivery platfo

44 To further demonstrate the capability of microneedle arrays as second generation biosensors we ha

45 formulation development for hydrogel-forming microneedle arrays containing esketamine.

46 The results showed that microneedle arrays could effectively deliver siRNA to re

47 Hydrogel-forming microneedle arrays facilitate transdermal delivery of dr

48 Microneedle arrays may represent a better way to deliver

49 or possible self-administration using coated microneedle arrays was investigated for skin-targeted de

50 Hydrogel-forming microneedle arrays were fully characterised for their me

51 It is anticipated that the technique of microneedle-assisted drug delivery will soon become rele

52 study represents a novel minimally invasive microneedle based cutaneous immunotherapy, which may pro

53 iled overview of designs and applications of microneedle based devices that have been approved or are

54 rds investigating the safety and efficacy of microneedle based systems are ongoing.

55 overview of clinical efforts and outcome of microneedle based systems.

56 to approval and commercialization of several microneedle based/assisted products for clinical use.

57 nge 0-630mg/dl, thus significantly improving microneedle-based biosensor performance with respect to

58 These microneedle-based electrodes are fixed in an epidermal p

59 The resulting microneedle-based enzyme electrode displays an interfere

60 s two-channel amperometric potentiostat with microneedle-based glucose and lactate biosensors housed

61 The resulting microneedle-based LOX biosensor displays an interference

62 ave the way for CKM and for the simultaneous microneedle-based monitoring of multiple diabetes-relate

63 This microneedle-based patch can sense activated thrombin and

64 A bio-responsive microneedle-based patch, integrated with a rhodamine-sta

65 nimal skin, confirming the resiliency of the microneedle-based sensor.

66 and ongoing clinical studies performed using microneedle-based technologies for cosmetic, therapeutic

67 In this work a novel self-powered microneedle-based transdermal biosensor for pain-free hi

68 Here we report the first mediated microneedles-based biosensor for minimally invasive cont

69 roribbons twist under irradiation, while the microneedles bend.

70 Hollow microneedles can help overcome the skin permeation barri

71 Application of topical products prior to microneedling can introduce immunogenic particles into t

72 ond approach, we used force-calibrated glass microneedles coated with apCAM ligands to guide growth c

73 he stability of influenza vaccine during the microneedle coating process, with a focus on the role of

74 ainst CD44 also retained functionality after microneedle coating, this form of siRNA was used in subs

75 iRNA lipoplex) was less functional following microneedle coating.

76 he strategy of delivering 5-ALA using coated microneedles could be a promising approach for photodyna

77 To increase drug delivery efficiency, a microneedle DEB (MNDEB) was developed by a conformal tra

78 toward the adhesion site, but the amount of microneedle deflection did.

79 e growth cone was measured by monitoring the microneedle deflection using an optical microscope.

80 study is the first to characterise pocketed microneedle delivery of a liquid formulation into human

81 ages for administration, safety and storage, microneedle delivery of M2e-flagellin fusion protein is

82 functional in vivo gene silencing following microneedle delivery of siRNA.

83 Herein, an autonomous and degradable, active microneedle delivery platform is introduced, employing m

84 h versatile and effective autonomous dynamic microneedle delivery technology offers considerable prom

85 ore shown, for the first time, that a hollow microneedle device can facilitate efficient and reproduc

86 The resulting CKM microneedle device displays an attractive analytical per

87 e first to explore the potential of a hollow microneedle device for the delivery and subsequent expre

88 ermal vaccine was delivered using a metallic microneedle device, AdminPen.

89 ion was done using the NanoPass MicronJet600 microneedle device.

90 iour of skin due to the rapid development of microneedle devices for drug delivery applications into

91 Microneedle devices have been proposed as a minimally in

92 explore the use of minimally-invasive steel microneedle devices to effectively deliver siRNA into sk

93 Dissolvable microneedle (DMN) patches for immunization have multiple

94 afe in vivo and quininib released from these microneedles effectively inhibits angiogenesis and RVP i

95 In particular the gold surface of the microneedles electrode has been modified in 3 subsequent

96 lase (OPH) enzyme-modified carbon paste (CP) microneedle electrodes for square wave voltammetric (SWV

97 o evaluate efficacy and pain associated with microneedle expedited PDT.

98 th after a single targeted injection using a microneedle for administration of a glaucoma medication

99 Clinical reports of microneedles for cosmetic applications including acne vu

100 This study evaluated the potential of coated microneedles for improved dermal delivery of 5-aminolevu

101 rporating electrospun fibers into dissolving microneedles for the first time.

102 With the ability to load a multitude of microneedle formulations, the device can serve as a plat

103 , sequestered on the nail surface and in the microneedle-generated pores, from which the active paylo

104 higher initial amount of PPIX in the coated microneedle group, about twice the amount of PPIX was ph

105 This polymer microneedle has no dermal toxicity.

106 Transcutaneous delivery of vaccines using microneedles has also shown promise and may be particula

107 The use of microneedles has facilitated the painless localized deli

108 , in addition to percutaneous drug delivery, microneedles have been considered as an efficient techni

109 Especially, microneedles have been widely studied and developed for

110 the design, development and applications of microneedles have exponentially increased in the recent

111 Platelet-rich plasma and microneedling have been investigated recently as potenti

112 A hollow microneedle (HM) was prepared to deliver a phenylephrine

113 or BT to (i) visualise liquid loading of the microneedles, (ii) determine residence time of a liquid

114 The results demonstrate that microneedle immunization induced strong humoral as well

115 mal injury, separately generated around each microneedle in the dermis.

116 The pyramidal polymer microneedle in this study was fully released in skin in

117 The SCS was accessed using microneedles in a minimally invasive procedure.

118 Despite rapid increase in the use of microneedles in dermatology, there are few data about th

119 emonstrate rapid dissolution kinetics of the microneedles in skin.

120 e, HAdV5-PyMSP1(4)(2), to mice using silicon microneedles induces equivalent or enhanced antibody res

121 d that, when actuated, the luminal unfolding microneedle injector provided a faster pharmacokinetic u

122 stible capsule, termed the luminal unfolding microneedle injector, which allows for the oral delivery

123 y rapidly propelling dissolvable drug-loaded microneedles into intestinal tissue using a set of unfol

124 eep cave formed in the basal portion of each microneedle, into which BCG powder could be packaged dir

125 ospheres into the supraciliary space using a microneedle is able to reduce IOP for one month as an al

126 A microneedle is secured within the injection station to c

127 The release kinetics of active microneedles is evaluated in vitro by measuring the amou

128 Microneedles is the technique of drug delivery enhanceme

129 The results reveal that the new microneedles lactate sensor holds interesting promise fo

130 elivery of just 350mug of 5-ALA using coated microneedles led to about 3.2-fold higher PPIX formation

131 In rats, microneedles loaded with a clinically available vaccine

132 single removable transdermal patch, bearing microneedles loaded with insulin and a non-degradable gl

133 on fields created by fibroblasts or actuated microneedles, M migrate towards the force source from se

134 Here, we adapt microneedle manipulation to exert local forces on the sp

135 ed with microdermabrasion (median, 6731 AU), microneedling (median, 5609 AU), and curettage (median,

136 Overall, our results show that hollow microneedle mediated intradermal delivery of polymeric N

137 Therefore, microneedle-mediated immunization has potential to both

138 Microneedle-mediated vaccine priming and resultant induc

139 We sought to optimize the synthesis of MH microneedles (MHMs) while maintaining the MH therapeutic

140 Polymeric microneedle (MN) arrays continue to receive growing atte

141 and evaluation of novel dissolving polymeric microneedle (MN) arrays for the facilitated delivery of

142 dermal delivery of NPs, via novel dissolving microneedle (MN) arrays has garnered interest in the pha

143 We availed of polymeric dissolving microneedle (MN) arrays laden with nano-encapsulated ant

144 Solid pyramidal microneedle (MN) arrays were fabricated with silk fibroi

145 delivery using bullet-shaped double-layered microneedle (MN) arrays with water-swellable tips.

146 We therefore sought to develop a dry-coated microneedle (MN) delivery system and combine it with top

147 This study developed a minimally-invasive microneedle (MN) patch for skin vaccination with virus-l

148 eliver the DNA to the nucleus of cells ii) a microneedle (MN) patch that will house the nanoparticles

149 art exendin-4 (Ex4) delivery device based on microneedle (MN)-array patches integrated with dual mine

150 An innovative microneedle (MN)-based cell therapy is developed for glu

151 In the present study, we demonstrate a microneedle (MN)-based cutaneous preventive allergy trea

152 We developed dissolving polymeric microneedles (MN) arrays to deliver GEN transdermally.

153 a (CAP)-mediated ICB therapy integrated with microneedles (MN) for the transdermal delivery of ICB.

154 Microneedles (MNs) allow transdermal delivery of otherwi

155 Microneedles (MNs) allow transdermal delivery of skin-im

156 Microneedles (MNs) have been investigated as a minimally

157 Microneedles (MNs) have been proposed as a suitable drug

158 id lipid nanoparticles (SLNs) and dissolving microneedles (MNs) to deliver antifilariasis drugs, name

159 Microneedles (MNs), as an effective minimally invasive d

160 perty of 15d-PGJ2 cream can be enhanced with microneedles (MNs).

161 In addition, the dimensions of the microneedles modified with the corresponding layers nece

162 niquely, heterogeneous arrays, consisting of microneedles of diverse composition, can be easily produ

163 oscopy established that coatings of 5-ALA on microneedles of the patch were uniform.

164 Recently-introduced biocompatible polymeric microneedles offer an efficient method for drug delivery

165 By coupling the microneedles operating under capillary-action with an en

166 ough cutaneous immunotherapy using PE-coated microneedles or not treated, and then orally challenged

167 nvestigate the influence of pulsative flows, microneedle parameters and synchronization on the effica

168 ed in participants who self-administered the microneedle patch (all p>0.05).

169 This study evaluated dissolvable microneedle patch (dMNP) delivery of hepatitis B vaccine

170 The biodegradable microneedle patch (MNP) is a novel technology for vaccin

171 In this study, we developed a dissolving microneedle patch (MNP) made of polyvinylpyrrolidone, du

172 an titres were similar at day 28 between the microneedle patch administered by a health-care worker v

173 41 [82%] of 50 [69-91]) after vaccination by microneedle patch application.

174 antigen in skin via intradermal injection or microneedle patch can enhance immune responses and reduc

175 Further development of the rapidly separable microneedle patch for self-administered, long-acting con

176 ten-fold lower vaccine dose administered by microneedle patch generated a weaker immune response com

177 e, we demonstrated that daily vaccination by microneedle patch induced a potent, balanced humoral imm

178 hicken and porcine skin demonstrate that the microneedle patch is suitable for monitoring potassium c

179 haemagglutinin per B vaccine strain) (1) by microneedle patch or (2) by intramuscular injection, or

180 (vaccine via health-care worker administered microneedle patch or intramuscular injection, or self-ad

181 dose of (4) inactivated influenza vaccine by microneedle patch self-administered by study participant

182 he first-in-man study on single, dissolvable microneedle patch vaccination against influenza.

183 es were significantly higher at day 28 after microneedle patch vaccination compared with placebo (all

184 and assess the safety and immunogenicity of microneedle patch vaccination using a rabies DNA vaccine

185 asked to the type of vaccination method (ie, microneedle patch vs intramuscular injection).

186 In rats, the microneedle patch was well tolerated, leaving little vis

187 Here, we report the design of a microneedle patch with rapidly separable biodegradable p

188 ntramuscular injection, or self-administered microneedle patch), overall incidence of solicited adver

189 scular injection, or received (3) placebo by microneedle patch, all administered by an unmasked healt

190 g magnesium microparticles loaded within the microneedle patch, as the built-in engine for deeper and

191 rage for at least 3weeks at 4 degrees C in a microneedle patch.

192 Skin immunization with microneedle patches (MN) is a novel and safe vaccination

193 Microneedle patches are designed to serve this need by c

194 Finally, biosensing microneedle patches associated with personalized drug th

195 These microneedle patches can be easily and painlessly applied

196 Microneedle patches containing 57 microneedles were coat

197 As a possible solution, microneedle patches containing an array of micron-sized

198 icity of biological sample acquisition using microneedle patches coupled with the simplicity of analy

199 Microneedle patches delivering preprogrammed doses may o

200 l methods to collect biomarker analytes from microneedle patches for analysis by integration into con

201 nt of other translational stimuli-responsive microneedle patches for drug delivery.

202 INTERPRETATION: Use of dissolvable microneedle patches for influenza vaccination was well t

203 Here, we propose the use of dissolving microneedle patches for simple and potentially cost-effe

204 merging antimicrobial transdermal and ocular microneedle patches have become promising medical device

205 lations into the dermis using antigen-coated microneedle patches is a promising and safe approach bec

206 We conclude that dissolving microneedle patches may provide an innovative approach t

207 We conclude that microneedle patches offer a powerful new technology that

208 ping countries and discusses advantages that microneedle patches offer for vaccination to address the

209 Microneedle patches provide an alternative to convention

210 Microneedle patches were at least as immunogenic as intr

211 In another method, microneedle patches were attached to form the bottom of

212 Microneedle patches were made out of cross-linked hydrog

213 Microneedle patches were shown to swell with water up to

214 Microneedle patches were well tolerated in the skin, wit

215 entrations in rats, 24 h post-application of microneedle patches with drug reservoir F3 and LW3, were

216 odified delivery systems such as transdermal microneedle patches, in situ forming injectable implants

217 To collect analytes from microneedle patches, the patches were mounted within the

218 development of point-of-care diagnostics and microneedle patches, will facilitate progress towards me

219 th the simplicity of analyte collection from microneedles patches integrated into conventional analyt

220 emitted in vivo to micropig skin at varying microneedle penetration depths, signal amplitudes, and c

221 ation depth and area of the breach caused by microneedle penetration following staining and optical i

222 ate the importance of subcutaneous tissue on microneedle performance and the need for representative

223 imentation studies that are used to evaluate microneedle performance do not consider the biomechanica

224 The Microneedle Photodynamic Therapy II (MNPDT-II) study was

225 his study progresses the translation of this microneedle platform to eventual clinical deployment.

226 me continuous ketone bodies monitoring (CKM) microneedle platform.

227 s and an associated lipophilic 'active' in a microneedle-porated nail.

228 Furthermore, with use of coated microneedles, PPIX was observed in deeper regions of the

229 0-minute incubation arm AK clearance for the microneedle pretreated side was 43% compared with 38% on

230 Photodynamic therapy with microneedle pretreatment at a 20-minute ALA incubation t

231 y outcome was to assess pain associated with microneedle pretreatment.

232 Trailing-edge detachment and pulling with a microneedle produced motion and deformation of the nucle

233 rofluidic, drop dispensing-based dissolvable microneedle production method that overcomes these issue

234 compared to untreated group, suggesting that microneedles promoted immune modulation towards the Th1

235 Started from the development of simple solid microneedles, providing microporation of stratum corneum

236 perianal skin with minimal pain using hollow microneedles, resulting in the increase of resting anal

237 incubation times, after pretreatment with a microneedle roller (200 um) vs a sham roller.

238 r for the future use of MH as a component of microneedle scaffolds.

239 esent work describes an attractive skin-worn microneedle sensing device for the minimally invasive el

240 This work presents a wearable microneedle sensor array for minimally invasive continuo

241 The new multimodal microneedle sensor array relies on unmodified and organo

242 Our results reveal that the new microneedle sensor holds considerable promise for contin

243 The potential applicability of this microneedle sensor toward minimally invasive monitoring

244 sertion of the MNA into the skin, individual microneedle shafts melted away by interstitial fluid fro

245 Treating the ear with microneedles showed permeation of siRNA in the skin and

246 ys demonstrated quininib released from these microneedles significantly (p<0.0001) inhibited ocular d

247 device consists of an assembly of pyramidal microneedle structures integrated with Pt and Ag wires,

248 th a lower dose of just 1.75mg 5-ALA, coated microneedles suppressed the growth of subcutaneous tumor

249 Following recovery from the microneedle surface, lamin A/C siRNA retained full activ

250 One method, the use of dissolving microneedle technologies, has the potential to achieve t

251 d the need for representative skin models in microneedle technology development.

252 demonstrate that skin vaccine delivery using microneedle technology induces mobilization of long live

253 Microneedle technology provides the opportunity for the

254 ular levels, using biomechanics and magnetic microneedle technology, and show for the first time that

255 vascular smooth muscle cells using magnetic microneedle technology.

256 es use of an array of silicon-dioxide hollow microneedles that are about one order of magnitude both

257 midity, glucose and pH sensors and polymeric microneedles that can be thermally activated to deliver

258 production of dissolving MNAs with undercut microneedles that can be tip-loaded with multiple biocar

259 titial fluid from the patient via integrated microneedles, the requirements from the integrated biose

260 open [corrected] facial granulomas following microneedle therapy for skin rejuvenation.

261 Microneedle therapy includes skin puncture with multiple

262 Because the microneedle therapy system is accessible for home use, h

263 izer (Vita C Serum; Sanitas Skincare) during microneedle therapy.

264 In this study we evaluated the potential of microneedles to deliver peanut protein extract (PE) into

265 microneedle and the patch backing allow the microneedles to efficiently penetrate skin under compres

266 Here, we use microneedles to pull on mammalian kinetochore-fibers and

267 to apply dense polymethylmethacrylate (PMMA) microneedles to the skin models in a controlled and repe

268 udies, the device consistently delivered the microneedles to the tissue without causing complete thic

269 s, various cosmeceuticals are applied before microneedling to enhance the therapeutic effects.

270 5) in splenocyte culture supernatants of the microneedle treated group as compared to untreated group

271 anaphylaxis were significantly lower in the microneedle treated mice as compared to untreated mice,

272 ine and mast cell protease-1 (MCPT-1) in the microneedles treated group.

273 irs for sustained topical drug delivery into microneedle-treated human nail.

274 EPD is based on ablative fractional laser or microneedle treatment of the skin to generate microchann

275 sweat can pass through an array of flexible microneedle type of sensors (50microm diameter) incorpor

276 his work shows that the pores created by the microneedle-type medical device, Nanopatch(R), are trans

277 Different microneedle types and application methods have been inve

278 e microtechnologies to fabricate micromilled microneedles (uMMNs) of stainless steel (SS) for precise

279 The tranexamic acid biocompatible polymer microneedle used in this study was fabricated from PVP a

280 1x10(6)needles/cm(2)) than state-of-the-art microneedles used for biosensing so far.

281 nificant need to find some adjuvants for the microneedle vaccination.

282 ymosan can be used as an immunostimulant for microneedle vaccination.

283 The biocompatible polymer microneedle was fabricated at 60 degrees C.

284 tration of these microspheres using a hollow microneedle was performed in the eye of New Zealand Whit

285 Quininib incorporation into these microneedles was 90%.

286 Protective efficacy with microneedles was found to be significantly better than t

287 The stability of M2e5x VLP-coated microneedles was maintained for 8weeks at room temperatu

288 ofile of quininib released in vitro from the microneedles was quantified by HPLC.

289 An array of five stainless steel pocketed microneedles was shown to possess sufficient capacity to

290 Delivery of TA to the SCS using microneedles was simple, effective, and not associated w

291 Microneedle patches containing 57 microneedles were coated with 5-ALA using an in-house de

292 imonidine at a constant rate for 35 days and microneedles were designed to penetrate through the scle

293 Quininib-HA microneedles were formulated via desolvation from quinin

294 Furthermore, mice treated with PE-coated microneedles were observed to retain integrity of their

295 directly correlated to the stiffness of the microneedle, which is consistent with a reinforcement me

296 testing of patches of transdermal core-shell microneedles-which were fabricated by the micromoulding

297 quininib was formulated into hyaluronan (HA) microneedles whose safety and efficacy was evaluated in

298 es cerevisiae, or poly (I:C) was coated on a microneedle with inactivated influenza virus, and then i

299 ation biosensors we have functionalized gold microneedles with nanocarbons at which mediated electron

300 ttage, microdermabrasion with abrasive pads, microneedling with dermarollers, ablative fractional las